US8987270B2 - Formulations of selective alpha-2 agonists and methods of use thereof - Google Patents
Formulations of selective alpha-2 agonists and methods of use thereof Download PDFInfo
- Publication number
- US8987270B2 US8987270B2 US13/606,637 US201213606637A US8987270B2 US 8987270 B2 US8987270 B2 US 8987270B2 US 201213606637 A US201213606637 A US 201213606637A US 8987270 B2 US8987270 B2 US 8987270B2
- Authority
- US
- United States
- Prior art keywords
- selective
- eye
- adrenergic receptor
- contact lens
- redness
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Abstract
Description
Claims (2)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/606,637 US8987270B2 (en) | 2009-07-27 | 2012-09-07 | Formulations of selective alpha-2 agonists and methods of use thereof |
PCT/US2013/058199 WO2014039635A1 (en) | 2012-09-07 | 2013-09-05 | Formulations of selective alpha-2 agonists and methods of use thereof |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/460,942 US8338421B2 (en) | 2008-08-01 | 2009-07-27 | Compositions and methods for reversing rebound hyperemia |
US12/928,749 US8765758B2 (en) | 2009-12-17 | 2010-12-17 | Compositions and methods for eye whitening |
US13/606,637 US8987270B2 (en) | 2009-07-27 | 2012-09-07 | Formulations of selective alpha-2 agonists and methods of use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/460,942 Continuation-In-Part US8338421B2 (en) | 2008-08-01 | 2009-07-27 | Compositions and methods for reversing rebound hyperemia |
Publications (2)
Publication Number | Publication Date |
---|---|
US20120328687A1 US20120328687A1 (en) | 2012-12-27 |
US8987270B2 true US8987270B2 (en) | 2015-03-24 |
Family
ID=47362058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/606,637 Active 2029-12-29 US8987270B2 (en) | 2009-07-27 | 2012-09-07 | Formulations of selective alpha-2 agonists and methods of use thereof |
Country Status (2)
Country | Link |
---|---|
US (1) | US8987270B2 (en) |
WO (1) | WO2014039635A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210338666A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine combinations and uses thereof |
US11833245B2 (en) | 2008-08-01 | 2023-12-05 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8445526B2 (en) * | 2011-02-03 | 2013-05-21 | Glaucoma & Nasal Therapies Llc | Compositions and methods for treatment of glaucoma |
US11026884B2 (en) * | 2018-01-24 | 2021-06-08 | Eye Therapies Llc | Methods for improving vision |
US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
WO2020041282A1 (en) * | 2018-08-22 | 2020-02-27 | Eye Therapies, Llc | Vasoconstriction compositions and methods of use |
EP4003341A4 (en) * | 2019-07-26 | 2023-08-30 | Allergan Sales, LLC | Compositions and methods for treatment of presbyopia |
EP4069220A4 (en) * | 2019-12-04 | 2024-04-24 | Restore Vision Llc | Ophthalmic formulations for the treatment of presbyopia |
Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663340A (en) | 1984-07-13 | 1987-05-05 | Henry Najer | Alpha-adrenoreceptor agonistic 2-[(2-cyclopropyl-5-methyl- or 2-cyclopropyl-5-chlorophenoxy)methyl]-2-imidazolines |
US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5300504A (en) | 1989-10-12 | 1994-04-05 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5304569A (en) | 1989-11-13 | 1994-04-19 | Orion-Yhtyma Oy | Compositions and their use in lowering intraocular pressure |
US5424078A (en) | 1988-11-29 | 1995-06-13 | Allergan, Inc. | Aqueous ophthalmic formulations and methods for preserving same |
US5561132A (en) | 1993-10-13 | 1996-10-01 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
US5712301A (en) | 1993-08-25 | 1998-01-27 | Orion-yhtyma Oy | Use of dexmedetomidine for treating ethanol-induced neurodegeneration |
US5804587A (en) | 1995-06-29 | 1998-09-08 | The Procter & Gamble Company | 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists |
US5885550A (en) * | 1998-07-02 | 1999-03-23 | Vallier; Deandra K. | Ophthalmic whitening solution |
US5914342A (en) | 1995-06-07 | 1999-06-22 | The Procter & Gamble Company | 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists |
US5916900A (en) | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
US5965595A (en) | 1993-07-01 | 1999-10-12 | The Procter & Gamble Company | 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists |
US6087361A (en) | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
US6110952A (en) | 1996-11-25 | 2000-08-29 | The Procter & Gamble Company | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists |
US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
US6162818A (en) | 1996-11-25 | 2000-12-19 | The Procter & Gamble Company | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US6242442B1 (en) * | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
US20010049369A1 (en) | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
US20020156076A1 (en) | 1997-12-04 | 2002-10-24 | Allergan Sales, Inc. | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors |
US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
US6534048B1 (en) | 1999-10-26 | 2003-03-18 | Curatek Pharmaceuticals Holding, Inc. | Topical clonidine preparation |
US6562855B1 (en) | 1999-06-11 | 2003-05-13 | Nicholas Peter Franks | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist |
US6562873B2 (en) | 2000-07-14 | 2003-05-13 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
US20030181354A1 (en) | 2002-01-31 | 2003-09-25 | Muhammad Abdulrazik | Method for central nervous system targeting through the ocular route of drug delivery |
US6627210B2 (en) | 2000-07-14 | 2003-09-30 | Allergan, Inc. | Compositions containing α-2-adrenergic agonist components |
US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
US20030229088A1 (en) | 2002-05-21 | 2003-12-11 | Gil Daniel W. | Novel methods and compositions for alleviating pain |
US6730065B1 (en) | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050026924A1 (en) | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050058696A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US6916811B2 (en) | 2001-11-30 | 2005-07-12 | Schering Corporation | Adenosine A2a receptor antagonists |
US20050244468A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US6982079B2 (en) | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US20060264442A1 (en) | 2005-05-18 | 2006-11-23 | Allergan, Inc. | Methods for the treatment of ocular and neurodegenerative conditions in a mammal |
US20070031472A1 (en) | 2004-04-30 | 2007-02-08 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20070203085A1 (en) | 2004-03-11 | 2007-08-30 | Florian Lang | Methods For Interfering With Fibrosis |
US7309706B2 (en) | 2002-06-19 | 2007-12-18 | Solvay Pharmaceuticals Gmbh | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins |
US20080020076A1 (en) | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
US20080131485A1 (en) | 2004-04-30 | 2008-06-05 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20080233053A1 (en) | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
WO2009022096A1 (en) | 2007-08-13 | 2009-02-19 | Orient Pharma (Samoa) Co, Ltd | Drug combinations for the treatment of sialorrhoea |
US20090176843A1 (en) | 2008-01-09 | 2009-07-09 | Sinha Santosh C | Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
US20090220611A1 (en) | 2005-09-30 | 2009-09-03 | Frederic Dargelas | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
US20100029659A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development,Inc. | Preferential vasoconstriction compositions and methods of use |
US7678829B2 (en) | 2004-05-25 | 2010-03-16 | Qlt Inc. | Oculoselective drugs and prodrugs |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070016292A1 (en) * | 2003-11-14 | 2007-01-18 | Edward Perez | Epithelium treatment methods and devices for treating the epithelium |
US20100197694A1 (en) * | 2008-08-01 | 2010-08-05 | Gerald Horn | Compositions and methods for treatment of diseases and conditions with increased vascular permeability |
-
2012
- 2012-09-07 US US13/606,637 patent/US8987270B2/en active Active
-
2013
- 2013-09-05 WO PCT/US2013/058199 patent/WO2014039635A1/en active Application Filing
Patent Citations (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663340A (en) | 1984-07-13 | 1987-05-05 | Henry Najer | Alpha-adrenoreceptor agonistic 2-[(2-cyclopropyl-5-methyl- or 2-cyclopropyl-5-chlorophenoxy)methyl]-2-imidazolines |
US5424078A (en) | 1988-11-29 | 1995-06-13 | Allergan, Inc. | Aqueous ophthalmic formulations and methods for preserving same |
US5300504A (en) | 1989-10-12 | 1994-04-05 | Allergan, Inc. | (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same |
US5021416A (en) | 1989-10-31 | 1991-06-04 | Allergan, Inc. | Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure |
US5304569A (en) | 1989-11-13 | 1994-04-19 | Orion-Yhtyma Oy | Compositions and their use in lowering intraocular pressure |
US5965595A (en) | 1993-07-01 | 1999-10-12 | The Procter & Gamble Company | 2-Imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists |
US5712301A (en) | 1993-08-25 | 1998-01-27 | Orion-yhtyma Oy | Use of dexmedetomidine for treating ethanol-induced neurodegeneration |
US5756503A (en) | 1993-10-13 | 1998-05-26 | Allergan | Methods for using (2-imidazolin-2-ylamino) Quinoxaline derivatives |
US5561132A (en) | 1993-10-13 | 1996-10-01 | Allergan | Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives |
US6117871A (en) | 1993-12-17 | 2000-09-12 | The Procter & Gamble Company | 6-(2-imidazolinylamino)quinoxaline compounds useful as alpha-2 adrenoceptor agonists |
US5605911A (en) | 1995-01-31 | 1997-02-25 | Washington University | Use of alpha-2 adrenergic drugs to prevent adverse effects of NMDA receptor hypofunction (NRH) |
US6087361A (en) | 1995-05-12 | 2000-07-11 | Allergan Sales, Inc. | Aryl-imidazolines and aryl-imidazoles useful as α-2 adrenergic agonists without cardiovascular side effects |
US5914342A (en) | 1995-06-07 | 1999-06-22 | The Procter & Gamble Company | 2-imidazolinylamino heterocyclic compounds useful as alpha-2 adrenoceptor agonists |
US6248741B1 (en) | 1995-06-28 | 2001-06-19 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6465464B2 (en) | 1995-06-28 | 2002-10-15 | Allergan, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury |
US6194415B1 (en) | 1995-06-28 | 2001-02-27 | Allergan Sales, Inc. | Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury |
US5804587A (en) | 1995-06-29 | 1998-09-08 | The Procter & Gamble Company | 6-(2-imidazolinylamino) quinolines useful as alpha-2 adrenoceptor agonists |
US5916900A (en) | 1995-06-29 | 1999-06-29 | The Procter & Gamble Company | 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists |
US5677321A (en) | 1996-02-29 | 1997-10-14 | Synaptic Pharmaceutical Corporation | 5- and 6-(2-imidazolin-2-ylamino) and -(2-thiazolin-2-ylamino)-benzothiazoles as alpha-2 adrenergic ligands |
US6159998A (en) | 1996-02-29 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
US6040451A (en) | 1996-02-29 | 2000-03-21 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
US5948804A (en) | 1996-02-29 | 1999-09-07 | Synaptic Pharmaceutical Corporation | Substituted indoles and uses thereof |
US6162818A (en) | 1996-11-25 | 2000-12-19 | The Procter & Gamble Company | 2-imidazolinylaminoindole compounds useful as alpha-2 adrenoceptor agonists |
US6110952A (en) | 1996-11-25 | 2000-08-29 | The Procter & Gamble Company | 2-imidazolinylaminobenzoxazole compounds useful as alpha-2 adrenoceptor agonists |
US20020156076A1 (en) | 1997-12-04 | 2002-10-24 | Allergan Sales, Inc. | Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B / 2C adrenergic receptors |
US5885550A (en) * | 1998-07-02 | 1999-03-23 | Vallier; Deandra K. | Ophthalmic whitening solution |
US6242442B1 (en) * | 1998-12-17 | 2001-06-05 | Alcon Laboratories, Inc. | Brinzolamide and brimonidine for treating ocular conditions |
US20020197300A1 (en) | 1999-02-22 | 2002-12-26 | Schultz Clyde L. | Drug delivery system for anti-glaucomatous medication |
US6562855B1 (en) | 1999-06-11 | 2003-05-13 | Nicholas Peter Franks | Anaesthetic formulation comprising an NMDA-antagoinst and an alpha-2 adrenergic agonist |
US6653354B2 (en) | 1999-07-29 | 2003-11-25 | Protexeon Limited | NMDA antagonist comprising xenon |
US6534048B1 (en) | 1999-10-26 | 2003-03-18 | Curatek Pharmaceuticals Holding, Inc. | Topical clonidine preparation |
US20010049369A1 (en) | 2000-02-10 | 2001-12-06 | Jablonski Monica M. | Brimonidine compositions and methods for retinal degeneration |
US6627210B2 (en) | 2000-07-14 | 2003-09-30 | Allergan, Inc. | Compositions containing α-2-adrenergic agonist components |
US20050026924A1 (en) | 2000-07-14 | 2005-02-03 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US6641834B2 (en) | 2000-07-14 | 2003-11-04 | Allergan Sales, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US6562873B2 (en) | 2000-07-14 | 2003-05-13 | Allergan, Inc. | Compositions containing therapeutically active components having enhanced solubility |
US6673337B2 (en) | 2000-07-14 | 2004-01-06 | Allergan, Inc. | Compositions containing alpha-2-adrenergic agonist components |
US6730065B1 (en) | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
US6916811B2 (en) | 2001-11-30 | 2005-07-12 | Schering Corporation | Adenosine A2a receptor antagonists |
US20030181354A1 (en) | 2002-01-31 | 2003-09-25 | Muhammad Abdulrazik | Method for central nervous system targeting through the ocular route of drug delivery |
US20080131483A1 (en) | 2002-01-31 | 2008-06-05 | Muhammad Abdulrazik | Enhancement of Drug Delivery to the Central Nervous System |
US7030149B2 (en) | 2002-04-19 | 2006-04-18 | Allergan, Inc. | Combination of brimonidine timolol for topical ophthalmic use |
US6982079B2 (en) | 2002-04-26 | 2006-01-03 | Allergan, Inc. | Compositions for treating hyperemia |
US20040132824A1 (en) | 2002-05-21 | 2004-07-08 | Allergan, Inc. | Novel methods and compositions for alleviating pain |
US20030229088A1 (en) | 2002-05-21 | 2003-12-11 | Gil Daniel W. | Novel methods and compositions for alleviating pain |
US7309706B2 (en) | 2002-06-19 | 2007-12-18 | Solvay Pharmaceuticals Gmbh | Method for the treatment of diseases requiring inhibition or a reduction in the activity of pH value-regulating bicarbonate transporter proteins |
US20080207627A1 (en) | 2003-06-25 | 2008-08-28 | Gil Daniel W | Methods of preventing and reducing the severity of stress-associated conditions |
US20080207628A1 (en) | 2003-06-25 | 2008-08-28 | Gil Daniel W | Methods of preventing and reducing the severity of stress-associated conditions |
US20040266776A1 (en) | 2003-06-25 | 2004-12-30 | Gil Daniel W. | Methods of preventing and reducing the severity of stress-associated conditions |
US20050020600A1 (en) | 2003-07-23 | 2005-01-27 | Scherer Warren J. | Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists |
US20050059664A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
US20050058696A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
US20070203085A1 (en) | 2004-03-11 | 2007-08-30 | Florian Lang | Methods For Interfering With Fibrosis |
US20070031472A1 (en) | 2004-04-30 | 2007-02-08 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US7589057B2 (en) | 2004-04-30 | 2009-09-15 | Allergan, Inc. | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems |
US20080131485A1 (en) | 2004-04-30 | 2008-06-05 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
US20050244474A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
US20050244468A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and related methods |
US7678829B2 (en) | 2004-05-25 | 2010-03-16 | Qlt Inc. | Oculoselective drugs and prodrugs |
US20080233053A1 (en) | 2005-02-07 | 2008-09-25 | Pharmalight Inc. | Method and Device for Ophthalmic Administration of Active Pharmaceutical Ingredients |
US20060264442A1 (en) | 2005-05-18 | 2006-11-23 | Allergan, Inc. | Methods for the treatment of ocular and neurodegenerative conditions in a mammal |
US20090220611A1 (en) | 2005-09-30 | 2009-09-03 | Frederic Dargelas | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same |
US20080020076A1 (en) | 2006-07-21 | 2008-01-24 | Khem Jhamandas | Methods and Therapies for Potentiating a Therapeutic Action of an Alpha-2 Adrenergic Receptor Agonist and Inhibiting and/or Reversing Tolerance to Alpha-2 Adrenergic Receptor Agonists |
WO2009022096A1 (en) | 2007-08-13 | 2009-02-19 | Orient Pharma (Samoa) Co, Ltd | Drug combinations for the treatment of sialorrhoea |
US20090176843A1 (en) | 2008-01-09 | 2009-07-09 | Sinha Santosh C | Substituted-aryl-2-phenylethyl-1h-imidazole compounds as subtype selective modulators of alpha 2b and/or alpha 2c adrenergic receptors |
WO2009124755A1 (en) | 2008-04-08 | 2009-10-15 | European Molecular Biology Laboratory (Embl) | Compounds with novel medical uses and method of identifying such compounds |
US20100029659A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development,Inc. | Preferential vasoconstriction compositions and methods of use |
US20100029663A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Compositions and methods for reducing activation of alpha-1 receptors |
US20100029661A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Anesthetic compositions and methods of use |
US20100029662A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development, Inc. | Vasoconstriction compositions and methods of use |
US20100028266A1 (en) | 2008-08-01 | 2010-02-04 | Alpha Synergy Development. Inc. | Composition and methods for treating allergic response |
Non-Patent Citations (93)
Title |
---|
A Useful New Topical Treatment for Glaucoma and Ocular Hypertension-Drug Ther Perspect 13(1):1-4, 1999. |
A Useful New Topical Treatment for Glaucoma and Ocular Hypertension—Drug Ther Perspect 13(1):1-4, 1999. |
Adding Dexmedetomidine to Lidocaines for Intravenous Regional Anesthesia, Dilek Memis, MS et. al, Anesth. Analg. 2004:98:835-40. |
AFT Pharmaceuticals Ltd., Brimonidine AFT. 2005; p. 1, para 2-3, 5 http://www.medsafe.govt.nz/Profs/Datasheet/b/Brimonidine-AFTeyedrops.pdf. |
Akasu et al., Reduction of the N-Type Calcuium Current by Noradrenaline in Neurones of Rabbit Vesical Parasympathetic Ganglia, Journal of Physiology, 1990, 426, 439-452. |
Alpha 1-receptors at pre-capillary resistance vessels of the human nasal mucosa, Johannssen V et al., Rhinology 1997; 35(4):161-65. |
Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline, Haenisch B. et al., Fundam Clin Pharmacol. Dec. 17, 2009. |
An Evaluation of Nasal Response Following Different Treatment Regimes of . . . , Morris S. et al., American Journal Rhinology, vol. 11, No. 2, Mar-Apr. 1997, pp. 109-115(. |
Bielory, Chirality in ocular agents, Current Opinion in Allergy and Clinical Immunology, Oct. 2007, 7(5), 418-423 (Abstract). |
Briminodine in the Treatment for Glaucoma and Ocular Hypertension-Drug Ther. Perspect. 13(1):1-4, 1999. |
Briminodine in the Treatment for Glaucoma and Ocular Hypertension—Drug Ther. Perspect. 13(1):1-4, 1999. |
Catecholemnines and Sympathomimetic Drugs-Goodman & Gilman's Pharmacology, Ch. 10; www.accessmedicine.com/popup.aspx?a1D-936314&pring=yes-chapter. |
Catecholemnines and Sympathomimetic Drugs—Goodman & Gilman's Pharmacology, Ch. 10; www.accessmedicine.com/popup.aspx?a1D-936314&pring=yes—chapter. |
Chang et al., Improved Corneal Penetration of Timolol by Prodrugs as a Means to Reduce Systemic Drug Load, 1987, 28(3), 487-491. |
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo-DD> Rees, et al., br. J. Pharmacol. (1990) 101, 746-752. |
Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo—DD> Rees, et al., br. J. Pharmacol. (1990) 101, 746-752. |
Correspondence a Propos De L'article: <<Traitement Des Clauclomes Par La Brimonidine>>, M. Detry-Morel et al., J. Fr. Opthamol. 2000; 23(8): 763-8. |
Correspondence A Propos De L'article: <<Traitement Des Glaucomes Par La Brimonidine>>, M. Detry-Morel Et C. Dutrieux< J Fr Ophtalmol.2001; 24(7): 748-9. |
Correspondence a Propos De L'article: >, M. Detry-Morel et al., J. Fr. Opthamol. 2000; 23(8): 763-8. |
Correspondence A Propos De L'article: >, M. Detry-Morel Et C. Dutrieux< J Fr Ophtalmol.2001; 24(7): 748-9. |
Crassous et al., Interest of a2-adrenergic agonists and antagonists in clinical practice: Background, facts and perspectives, Current Topics in Medicinal Chemistry, Jan. 2007, 7(2), 187-194 (Abstract). |
Dexmedetomidine Enhances the Local Anesthetic Action of Lidocaine via . . . Tatsushi Yoshitomi DDS et al., Anesth. Analg. 2008I 107:96-101. |
Donello et al., a2-Adrenoceptor Agonists Inhibit Vitreal Glutamate and Aspartate Accumulation and Preserve Retinal Function after Transient Ischemia, Journal of Pharmacology and Experimental Therapeutics, 2011, 296(1), 216-223. |
Dong et al., a2 Adrenergic Modulation of NMDA Receptor Function as a Major Mechanism of RGC Protection in Experimental Glaucoma and Retinal Excitotoxicity, Investigative Ophthalmology & Visual Science, Oct. 2008, 49(10), 4515-4522. |
Forster, et al., Adrenergic Alpha1, and Alpha2 Binding Sites are Present in Bovine Retinal Blood Vessels, Investigative Ophthalmology & Visual Science, 1987, 28(11), 1741-1746. |
Freeman, Hypoxic-ischaemic brain injury (HIBI) after cardiopulmonary arrest, Current Anaesthesia and Critical Care, 2007, 18(5-6), 261-276 (Abstract). |
Gentili et al., Agonists and antagonists targeting the different a2-adrenoceptor subtypes, Current Topics in Medicinal Chemistry, Jan. 2007, 7(2), 163-186 (Abstract). |
Georgiou et al., Changes in NMDA receptor contribution to synaptic transmission in the brain in a rat model of glaucoma, Neurobiology of Disease, Sep. 2010, 39(3), 344-351 (Abstract). |
Gilsbach et al., Genetic dissection of a2-adrenoceptor functions in adrenergic versus nonadrenergic cells, Molecular Phar 2009, 75(5), p. 1160-1170. |
Hamasaki et al., Dual a2-Adrenergic Agonist and al-Adrenergic Antagonist Actions of Dexmedetomidine on Human Isolated Endothelium-Denuded Gastroepiploic Arteries, Anesth Analg, 2002, 94, 1434-1440. |
Huang et al., The two sides of cytokine signaling and glaucomatous optic neuropathy, j ocul biol dis inform, 2009, 2, 98-103. |
Inhibition of a-adrenergic vasoconstriction in exercising human thigh muscles-D. Walter Wray, et al., J. Physiol. 555, 2 pp. 545-564 (2003). |
Inhibition of a-adrenergic vasoconstriction in exercising human thigh muscles—D. Walter Wray, et al., J. Physiol. 555, 2 pp. 545-564 (2003). |
Interactions Between CA2+ and H+ and Functional Consequences in Vascular Smooth Muscle-C. Austin and S. Wray, Journ. of Amer. Heart Association (Circ. Res. 2000; 86:355-363). |
Interactions Between CA2+ and H+ and Functional Consequences in Vascular Smooth Muscle—C. Austin and S. Wray, Journ. of Amer. Heart Association (Circ. Res. 2000; 86:355-363). |
Jin et al., Ocular a2-receptor subclasses and antiglaucoma efficacy, Journal of Ocular Pharmacology, 1994, 10(1), 359-369 (Abstract). |
Jin et al., Ocular hypotensive effects of medetomidine and its analogs, Journal of Ocular Pharmacology 1991, 7(4) 285-296 (Abstract). |
Kost et al., Procedural Sedation and Analgesia in the Pediatric Emergency Department: A Review of Sedative Pharmacology, Clinical Pediatric Emergency Medicine, Dec. 2010, 11(4), 233-243 (Abstract). |
Laengle et al., GLC756 decreases TNF-alpha via an alpha2 and beta2 adrenoceptor related mechanism, Experimental eye research, Nov. 2006, 83(5), 1246-1251 (Abstract). |
Lehtimaeki et al., In vitro and in vivo profiling of fadolmidine, a novel potent a2-adrenoceptor agonist with local mode of action, European Journal of Pharmacology 2008, 599(1-3), 65-71 (Abstract). |
Li et al., A Study of the Relationship between Cornea Permeability and Eye Irritation Using Membrance-Interaction QSAR Analysis, Toxicological Sciences, 2005, 88(2), 434-446. |
Long-term use of oxy- and xylometazoline nasal sprays induces rebound swelling, tolerance, and nasal hyperreactivity, Graf P., Rhinology 1996, 34(1):9-13. |
Loots, Agents for sedation in ophthalmic surgery: A review of the pharmacodynamics and clinical applications, Current Anaesthesia and Critical Care, 2006, 17(3-4), 179-190 (Abstract). |
MacDonald et al., Comparison of the cardiovascular effects of the a2-adrenoceptor agonist, dexmedetomidine, in rats and rabbits, Drug Development Research 1993, 28(4), 473-477 (Abstract). |
Mechanism of decongestant activity of x2-adrenoceptor agnosits, Corboz M.R. et al., Pulmonary Pharmacology & Therapeutics 21 (2008) 449-454. |
Medical Management of Chronic Rhinosinusitus-Jean P. Fong, MD, Matthew Ryan, MD (May 2006). |
Medical Management of Chronic Rhinosinusitus—Jean P. Fong, MD, Matthew Ryan, MD (May 2006). |
Mowafi et al., Effect of dexmedetomidine premedication on the intraocular pressure changes after succinylcholine and intubation, British Journal of Anaesthesia, Apr. 2008, 100(4), 485-489. |
Mowafi et al., Remifentanil obtunds intraocular pressure rises associated with suxamethonium, British Journal of Anaesthesia, Sep. 2008, 101(3), 432-433. |
Myogenic Tone and Reactivity of the Rat Opthalmic Artery-Y.P.R. Jarajapu, M.B. Grant, and H.J. Knot Invest. Opth. & Visual Science, Jan. 2004, vol. 45, No. 1. |
Myogenic Tone and Reactivity of the Rat Opthalmic Artery—Y.P.R. Jarajapu, M.B. Grant, and H.J. Knot Invest. Opth. & Visual Science, Jan. 2004, vol. 45, No. 1. |
Niemi et al., Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs, International Journal of Pharmaceutics 2005, 29, 121-127. |
Ogidigben et al., Comparative effects of alpha-2 and DA-2 agonists on intraocular pressure in pigmented and nonpigmented rabbits, Journal of Ocular Pharmacology 1993, 9(3), 187-99 (Abstract). |
Paris et al., The Anesthetic Effects of Etomidate: Species-Specific Interaction with a2-Adrenoceptors, Anesth Analg. 2007, 105(6), 1644-1649. |
Pate et al., Ophthalmic arachidonylethanolamide decreases intraocular pressure in normotensive rabbits, Current eyer research Sep. 1995, 14(9), 791-797 (Abstract). |
Penha et al., Retinal and ocular toxicity in ocular application of drugs and chemicals-Part I: Animal models and toxicity assays, Ophthalmic Research, Jul. 2010, 44(2), 82-104 (Abstract). |
Penha et al., Retinal and ocular toxicity in ocular application of drugs and chemicals—Part I: Animal models and toxicity assays, Ophthalmic Research, Jul. 2010, 44(2), 82-104 (Abstract). |
Pertovaara, Antinociceptive Properties of Fadolmidine (MPV-24-26), a Novel a2-Adrenoceptor Agonist, CNS Drug Reviews, 2004, 10(2), 117-126. |
Pharmacological Characterization of Postjunctional a-Adrenoceptors in . . . , Corboz M.R. et al., American Jour of Rhinology, vol. 19, No. 5, Sep.-Oct. 2005, pp. 495-502. |
Postjuntional a2-adrenoceptors in blood ve3ssels of human nasal mucosa, Ichimura K. et al., Arch Otorhinolaryngol (1988) 245:127-131. |
Potent a2A-Adrenoceptor-Mediated Vacoconstriction by Brimonidine in Porcine Ciliary Arteries, Anna Wikberg-Matsson, et al., IOVS, 2001, vol. 42, No. 9, 2049-55. |
Potter et al., Review: Alpha2 and DA2 agonists as antiglaucoma agents: Comparative pharmacology and clinical potential, Journal of Ocular Pharmacology, 1990, 6(3), 251-257 (Abstract). |
Prevent Drugs from Going Missing in Action-Mark B. Abelson, MD, and Sarah A. Rosner MPH; Review of Opthalmology; www.revophth.com/index.asp?page1-357.htm. |
Prevent Drugs from Going Missing in Action—Mark B. Abelson, MD, and Sarah A. Rosner MPH; Review of Opthalmology; www.revophth.com/index.asp?page1—357.htm. |
Prospective Study of the Association Between Sleep-Disordered Breathing and Hypertension-P. Peppard, et. al., The New England J. of Med, vol. 342, No. 19:1378:1384 (2000). |
Prospective Study of the Association Between Sleep-Disordered Breathing and Hypertension—P. Peppard, et. al., The New England J. of Med, vol. 342, No. 19:1378:1384 (2000). |
Rhinitis Medicamentosa-JT Ramey, E Bailen, RF LOckey, J. Investig. Allergol. Clin. Immunol. 2006; vol. 16(3); 148-155. |
Rhinitis Medicamentosa—JT Ramey, E Bailen, RF LOckey, J. Investig. Allergol. Clin. Immunol. 2006; vol. 16(3); 148-155. |
Robertson, Standing sedation and pain management for ophthalmic patients, Veterinary Clinics of North America-Equine Practice, Aug. 2004, 20(2), 485-497 (Abstract). |
Robertson, Standing sedation and pain management for ophthalmic patients, Veterinary Clinics of North America—Equine Practice, Aug. 2004, 20(2), 485-497 (Abstract). |
Rosa et al., Brimonidine evokes hetrogenous vasomotor response of retinal arterioles: diminished nitric oxide-mediated vasodilation when size goes small, Am J Physiol Heart Cir Physiol 2006, 291, H231-H238. |
Ruffolo et al., a-Adrenoceptors, Pharmacology and Therapeutics, 1994, 61(1-2), 1-64 (Abstract). |
Sato et al., In Silico Functional Profiling of Small Molecules and Its Applications, Journal of Medical Chemistry 2008, 51(24), 7705-7716 (Abstract). |
Saylor et al., Experimental and Clinical Evidence for Brimonidine as an Optic Nerve and REtinal Neuroprotective Agent, Arch Ophthalmol, Apr. 2009, 127(4), 402-406. |
Schoewald et al., Relationship between Steroid Permeability across Excised Rabbit Cornea and Octanol-Water Partition Coefficients, Journal of Pharmaceutical Scienses, Jun. 1978, 67(6), 786-788. |
Shirasaka et al., Activation of a G Protein-coupled Inwardly Rectifying K+ Current and Suppression of lh Contribute to Dexmedetomidine-induced Inhibition of Rat Hypothalamic Paraventricular Nucleus Neurons, Anesthesiology, 2007, 107, 605-615. |
Silent Bedpartners-Nancy A. Collop, Chest 2002; 122, 1111-1112. |
Silent Bedpartners—Nancy A. Collop, Chest 2002; 122, 1111-1112. |
Stamer et al., Cultured human trabecular meshwork cells express functional alpha 2A adrenergic receptors, Investigative ophthalmology & visual science Nov. 1996, 37(12), 2426-2433 (Abstract). |
The Effect of Correction of Sleep-Disordered Breathing on Bp in Untreated Hypertension-K. Mae Hla, J.B. Skatrud, L. Finn, M. Palta and T. Young, Chest 2002:122 1125-1135. |
The Effect of Correction of Sleep-Disordered Breathing on Bp in Untreated Hypertension—K. Mae Hla, J.B. Skatrud, L. Finn, M. Palta and T. Young, Chest 2002:122 1125-1135. |
Traitment Des Glaucomes Par La Briminodine (Alphagan 0.2%)-M. Detry-Morel, C. Dutrieux, J. Fr. Opthamol., 2000; 23, 8, 763-768. |
Traitment Des Glaucomes Par La Briminodine (Alphagan 0.2%)—M. Detry-Morel, C. Dutrieux, J. Fr. Opthamol., 2000; 23, 8, 763-768. |
Trendelenburg et al., a2-Adrenoceptor-mediated inhibition of cultured sympathetic neurons: changes in a2A/D-adrenoceptor-deficient mice, Naunyn-Schmiedeberg's Arch Pharmacology, 2011, 363, 110-119. |
Tripathi et al., Role of receptors in the trabecular meshwork of the eye as targeted to the development of antiglacoma therapy, Drug Development Research, 1992, 27(3), 1991-228 (Abstract). |
U.S. Appl. No. 09/948,001, filed Sep. 6, 2001, Chow et al. |
Vaidyanathan S. et al., Fluticasone Reverses Oxymetazoline-induced Tachyphylaxis of Response and Rebound Congestion, American Journal of Respiratory and Critical Care Medicine vol. 182, 19-24, 2010. |
Vasopressin-Induced Vasoconstriction; Two Concentration-Dependen Signaling Pathways-Kyle K. Henderson and Kenneth L. Bryon, J. Appl. Physiol. 102: 1402-1409, 2007. |
Vasopressin-Induced Vasoconstriction; Two Concentration-Dependen Signaling Pathways—Kyle K. Henderson and Kenneth L. Bryon, J. Appl. Physiol. 102: 1402-1409, 2007. |
Verbruggen et al., The effect of intravenous medetomidine on pupil size and intraocular pressure in normotensive dogs, Veterinary Quarterly 2000, 22(3), 179-180 (Abstract). |
Weber et al., Neuroprotective effects of a2-adrenergic receptor agonists, Drug News and Perspectives, Apr. 2007, 20 (3), 149-154 (Abstract). |
Wirostoko et al., The Vascular Theory in Glaucoma, Glaucoma Today, Apr. 2009, 25-27. |
Wong et al., Design and synthesis of alpha2 adrenoceptor agonists, Book of Abstracts, 213th ACS National Meeting, San Francisco, Apr. 13-17, 1997, MEDI-023, American Chemical Society: Washington, D.C., (Abstract). |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11833245B2 (en) | 2008-08-01 | 2023-12-05 | Eye Therapies Llc | Vasoconstriction compositions and methods of use |
US20210338666A1 (en) * | 2020-04-30 | 2021-11-04 | Eye Therapies, Llc | Brimonidine combinations and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
WO2014039635A1 (en) | 2014-03-13 |
US20120328687A1 (en) | 2012-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US8987270B2 (en) | Formulations of selective alpha-2 agonists and methods of use thereof | |
JP7358221B2 (en) | Compositions and methods for treating presbyopia | |
US8765758B2 (en) | Compositions and methods for eye whitening | |
EP2680829B1 (en) | Compositions and methods for non-surgical treatment of ptosis | |
JP6800939B2 (en) | Methods and Compositions for Daily Ophthalmic Administration of Phentolamine to Improve Visual Function | |
CN103068364B (en) | Bimatoprost without preservative and timolol solution | |
AU2011282683B2 (en) | Preservative free brimonidine and timolol solutions | |
US20050239745A1 (en) | Novel topical ophthalmic formulations | |
US20120277239A1 (en) | Compositions and Methods for Improving Night Vision | |
JP2022504746A (en) | Compositions and Methods for the Treatment of Presbyopia | |
JP4905616B2 (en) | Eye drops for soft contact lenses | |
WO2018147409A1 (en) | Aqueous composition for eye drops and nasal drops | |
US20140038974A1 (en) | Compositions and Methods for Eye Whitening | |
WO2015050670A1 (en) | Compositions and mehthods for eye whitening | |
JP2024515714A (en) | Methods and compositions for treating mydriasis, glaucoma, and other ocular conditions - Patents.com | |
WO2022249069A1 (en) | Low-dose carbachol ophthalmic compositions with cumulative effect | |
JP5475958B2 (en) | Preventive or therapeutic agent for visual impairment | |
JP2021517139A (en) | Usage of Selective SYK Inhibitors and Pharmaceutical Compositions | |
WO2019135927A1 (en) | Contact lens compositions and methods for the treatment of presbyopia | |
JP2010065011A (en) | Inhibitor of epithelial cytotoxicity, and use thereof | |
JP2014024871A (en) | Preventing or treating agent of visual function impairment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ALPHA SYNERGY DEVELOPMENT, INC., CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:HORN, GERALD;REEL/FRAME:028916/0839 Effective date: 20120828 |
|
AS | Assignment |
Owner name: EYE THERAPIES LLC, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALPHA SYNERGY DEVELOPMENT, INC.;REEL/FRAME:034742/0866 Effective date: 20121015 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE UNDER 1.28(C) (ORIGINAL EVENT CODE: M1559); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
FEPP | Fee payment procedure |
Free format text: PETITION RELATED TO MAINTENANCE FEES GRANTED (ORIGINAL EVENT CODE: PTGR); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE UNDER 1.28(C) (ORIGINAL EVENT CODE: M1559); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
REFU | Refund |
Free format text: REFUND - PAYMENT OF MAINTENANCE FEE UNDER 1.28(C) (ORIGINAL EVENT CODE: R1559); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 8 |